surmount trials tirzepatide SURMOUNT-4 results just published in @JAMA_current 🛑Stopping #tirzepatide leads to regain of the majority of the lost weight. Is this a surprising result ⁉️ No #Obesity is a chronic disease and requires Presented today at #ECO2026 ⤵️

Note: same dose pricing may not apply during promotional periods or discounts

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction compared with placebo at one year, according to results from a large clinical trial.

Of the 19 studies, nine studies reported a significant increase in serum GLP-1 levels

For example, semaglutide and empagliflozin showed no significant difference in 3-point MACE (HR 1.05

A 55-day review timeline compared to the standard 10-12 months is not just an administrative achievement

This condition carries a global mortality rate of approximately 8% and is characterized by significantly elevated creatine kinase (CK) levels, often rising to five times the normal upper limit or higher